Evidence map›Paper›PMID 34777582›Full record

ArticleTherapeutic advances in medical oncology2021

COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry.

Laia Garrigós, Cristina Saura, Clara Martinez-Vila, Alberto Zambelli, Mark Bower, Barbara Pistilli, Matteo Lambertini, Diego Ottaviani, Nikolaos Diamantis, Ailsa Lumsden and 58 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in medical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Cancer management during the COVID-19 world pandemic.Cancer immunology, immunotherapy : CII · 2023
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

68 authors at 20 institutions in 7 countries.

Laia GarrigósDepartment of Medical Oncology, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Cristina SauraHead Breast Cancer Unit, Vall d'Hebron University Hospital and Principal Investigator Breast Group, Vall d'Hebron Institute of Oncology (VHIO), Passeig Vall d'Hebrón 119-129, 08035 Barcelona, Spain.
Clara Martinez-VilaDepartment of Oncology, Hospital Althaia Manresa, Barcelona, Spain.
Alberto ZambelliOncology Unit, ASST Papa Giovanni XXIII, Bergamo, Italy.
Mark BowerDepartment of Oncology and National Centre for HIV Malignancy, Chelsea and Westminster Hospital, London, UK.
Barbara PistilliDepartment of Medical Oncology, Institute Gustave-Roussy, Villejuif, France.
Matteo LambertiniDepartment of Medical Oncology, UOC Clinica di Oncologia Medica, IRCCS Policlinico San Martino Hospital, Genoa, Italy.ORCID https://orcid.org/0000-0003-1797-5296
Diego OttavianiCancer Division, University College London Hospitals, London, UK.
Nikolaos DiamantisMedical Oncology, Barts Health NHS Trust, London, UK.
Ailsa LumsdenTranslational Oncology & Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.
Sonia PernasDepartment of Medical Oncology, Catalan Institute of Oncology, L'Hospitalet, Spain.ORCID https://orcid.org/0000-0002-1485-5080
Daniele GeneraliMultidisciplinary Breast Pathology and Translational Research Unit, ASST Cremona, Casalmaggiore, Italy.
Elia SeguíDepartment of Medical Oncology, Hospital Clinic, Barcelona, Spain.
Gemma ViñasDepartment of Medical Oncology, Catalan Institute of Oncology, University Hospital Josep Trueta, Girona, Spain.
Eudald FelipDepartment of Medical Oncology, Catalan Institute of Oncology, Badalona, Spain.
Ana SanchezDepartment Medical Oncology, Hospital XII de Octubre, Madrid, Spain.
Gianpiero RizzoMedical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.
Armando SantoroIRCCS Humanitas Research Hospital, Humanitas Cancer Center, Milan, Italy.
Alessio CortelliniDepartment of Biotechnology and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Ylenia PeroneMedical Oncology, Velindre Cancer Centre, Cardiff, UK.
John ChesterMedical Oncology, Velindre Cancer Centre, Cardiff, UK.
Maria IglesiasDepartment of Oncology, Hospital Universitario Son Llatzer, Palma de Mallorca, Spain.
Marta BettiResearch Infrastructure, Research and Innovation Department, Azienda Ospedaliera "SS Antonio e Biagio e Cesare Arrigo", Alessandria, Italy.
Bruno VincenziDepartment of Oncology, University "Campus Bio-Medico", Rome, Italy.
Michela LibertiniMedical Oncology Unit, Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Italy.
Francesca MazzoniDepartment of Oncology, Careggi University Hospital, Florence, Italy.
Federica ZorattoMedical Oncology, Santa Maria Goretti Hospital, Latina, Italy.
Rossana BerardiOncology Clinic, Università Politecnica Delle Marche, Ospedali Riuniti Di Ancona, Ancona, Italy.
Annalisa GuidaStruttura Complessa di Oncologia Medica e Traslazionale, Azienda Ospedaliera Santa Maria di Terni, Italy.
Rachel WuerstleinDepartment of Gynecology and Obstetrics, Breast Center and Gynecological Cancer Center and CCC Munich, University Hospital Munich, Munich, Germany.
Angela LoizidouDepartment of Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Belgium.
Rachel SharkeyDepartment of Oncology and National Centre for HIV Malignancy, Chelsea and Westminster Hospital, London, UK.
Juan Aguilar CompanyDepartment of Medical Oncology, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.ORCID https://orcid.org/0000-0002-9838-1950
Marta MatasDepartment of Oncology, Hospital Althaia Manresa, Barcelona, Spain.
Chiara SaggiaDepartment of Translational Medicine, University of Piemonte Orientale, Azienda Ospedaliero-Universitaria Maggiore della Carità, Novara, Italy.
Lorenzo ChiudinelliOncology Unit, ASST Papa Giovanni XXIII, Bergamo, Italy.
Emeline Colomba-BlamebleDepartment of Medical Oncology, Institute Gustave-Roussy, Villejuif, France.
Myria GalaziCancer Division, University College London Hospitals, London, UK.
Uma MukherjeeMedical Oncology, Barts Health NHS Trust, London, UK.
Mieke Van HemelrijckTranslational Oncology & Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.
Mar MarinDepartment of Medical Oncology, Catalan Institute of Oncology, L'Hospitalet (Barcelona), Spain.
Carla StrinaMultidisciplinary Breast Pathology and Translational Research Unit, ASST Cremona, Casalmaggiore, Italy.
Aleix PratDepartment of Medical Oncology, Hospital Clinic, Barcelona, Spain.
Helena PlaDepartment of Medical Oncology, Catalan Institute of Oncology, University Hospital Josep Trueta, Girona, Spain.
Eva Maria CiruelosDepartment Medical Oncology, Hospital XII de Octubre, Madrid, Spain.
Alexia BertuzziIRCCS Humanitas Research Hospital, Humanitas Cancer Center, Milan, Italy.
Lucia Del MastroBreast Unit, IRCCS Policlinico San Martino Hospital, Genoa, Italy.
Giampiero PorzioMedical Oncology Unit, San Salvatore Hospital, L'Aquila, Italy.
Thomas Newsom-DavisDepartment of Oncology and National Centre for HIV Malignancy, Chelsea and Westminster Hospital, London, UK.
Isabel RuizDepartment of Infectious Diseases, Vall d'Hebron University Hospital, Barcelona, Spain.
Maria Belen DelanyDepartment of Oncology, Hospital Althaia Manresa, Barcelona, Spain.
Marco KrengliDivision of Radiotherapy, Department of Translational Medicine, University of Eastern Piedmont and Hospital "Maggiore della Carità", Novara, Italy.
Vittoria FotiaOncology Unit, ASST Papa Giovanni XXIII, Bergamo, Italy.
Alessandro ViansoneDepartment of Medical Oncology, Institute Gustave-Roussy, Villejuif, France.
Neha ChopraCancer Division, University College London Hospitals, London, UK.
Margarita RomeoDepartment of Medical Oncology, Catalan Institute of Oncology, Badalona, Spain.
Ramon SalazarDepartment of Medical Oncology, Catalan Institute of Oncology, L'Hospitalet (Barcelona), Spain.
Ignacio PerezDepartment of Oncology, Hospital Althaia Manresa, Barcelona, Spain.
Francesca d'AvanzoDepartment of Translational Medicine, University of Piemonte Orientale, Azienda Ospedaliero-Universitaria Maggiore della Carità, Novara, Italy.
Michela FranchiOncology Unit, ASST Papa Giovanni XXIII, Bergamo, Italy.
Manuela MilaniMultidisciplinary Breast Pathology and Translational Research Unit, ASST Cremona, Casalmaggiore, Italy.
Fanny PommeretDepartment of Medical Oncology, Institute Gustave-Roussy, Villejuif, France.
Marco TucciDepartment of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro, Bari, Italy.ORCID https://orcid.org/0000-0003-4008-4897
Paolo PedrazzoliMedical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.
Nadia HarbeckDepartment of Gynecology and Obstetrics, Breast Center and Gynecological Cancer Center and CCC Munich, University Hospital Munich, Munich, Germany.ORCID https://orcid.org/0000-0002-9744-7372
Daniela FerranteDepartment of Translational Medicine, Unit of Medical Statistics, University of Piemonte Orientale and Cancer Epidemiology, CPO Piemonte, Novara, Italy.
David J PinatoDivision of Surgery and Cancer, Hammersmith Hospital, Imperial College London, London, UK.
Alessandra GennariDepartment of Translational Medicine, University of Piemonte Orientale, Azienda Ospedaliero-Universitaria Maggiore della Carità, Novara, Italy.
Università degli Studi del Piemonte Orientale “Amedeo Avogadro” · ITInstitut Gustave Roussy · FRAlthaia · ESHumanitas University · ITInstitut Català d'Oncologia · ESInstitut Català d'Ornitologia · ESKing's College London · GBRoyal London Hospital · GBUniversity of Pavia · ITBarts Health NHS Trust · GBChelsea and Westminster Hospital · GBHospital Clínic de Barcelona · ESInstitut d'Investigació Biomédica de Bellvitge · ESOspedale Papa Giovanni XXIII · ITResearch Institute Hospital 12 de Octubre · ESSan Salvatore Hospital · ITVelindre Cancer Centre · GBAzienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo · ITAzienda Ospedaliera S.Maria · ITAzienda Ospedaliero-Universitaria Careggi · IT

Funding

Cancer Research UK 30195Wellcome Trust
6 · The paper itself

Abstract

backgroundCancer patients are at higher risk of COVID-19 complications and mortality than the rest of the population. Breast cancer patients seem to have better prognosis when infected by SARS-CoV-2 than other cancer patients.

methodsWe report a subanalysis of the OnCovid study providing more detailed information in the breast cancer population.

resultsWe included 495 breast cancer patients with a SARS-CoV-2 infection. Mean age was 62.6 years; 31.5% presented more than one comorbidity. The most frequent breast cancer subtype was luminal-like (

conclusionIn the context of COVID-19, our data confirm that breast cancer patients appear to have lower complications and mortality rate than expected in other cancer populations. Most breast cancer patients can be safely treated for their neoplasm during SARS-CoV-2 pandemic. Oncological treatment has no impact on the risk of SARS-CoV-2 complications, and, especially in the curative setting, the treatment should be modified as little as possible.

Indexed as

breast cancerCOVID-19COVID-19 outcomesOnCovidSARS-CoV-2

Identifiers

PMID34777582
PMCPMC8573484
OpenAlexW3209172379

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.